Source link : https://www.newshealth.biz/health-news/glp-1-ras-reduce-hyperkalemia-risk-prolong-rasi-use/
TOPLINE: In patients with type 2 diabetes (T2D), the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and sustained use of guideline-recommended renin-angiotensin system inhibitors (RASis) compared with the use of dipeptidyl peptidase-4 inhibitors (DPP-4is). METHODOLOGY: Hyperkalemia is a common electrolyte complication in patients with T2D, particularly […]
Author : News Health
Publish date : 2024-08-16 11:03:21
Copyright for syndicated content belongs to the linked Source.
Categories